IBDEI0O4 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11881,1,4,0)
 ;;=4^117.5
 ;;^UTILITY(U,$J,358.3,11881,1,5,0)
 ;;=5^Cryptococcosis
 ;;^UTILITY(U,$J,358.3,11881,2)
 ;;=^29608
 ;;^UTILITY(U,$J,358.3,11882,0)
 ;;=288.02^^82^781^5
 ;;^UTILITY(U,$J,358.3,11882,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11882,1,4,0)
 ;;=4^288.02
 ;;^UTILITY(U,$J,358.3,11882,1,5,0)
 ;;=5^Cyclic Neutropenia
 ;;^UTILITY(U,$J,358.3,11882,2)
 ;;=^334039
 ;;^UTILITY(U,$J,358.3,11883,0)
 ;;=078.5^^82^781^6
 ;;^UTILITY(U,$J,358.3,11883,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11883,1,4,0)
 ;;=4^078.5
 ;;^UTILITY(U,$J,358.3,11883,1,5,0)
 ;;=5^Cytomegaloviral Disease
 ;;^UTILITY(U,$J,358.3,11883,2)
 ;;=^30676
 ;;^UTILITY(U,$J,358.3,11884,0)
 ;;=110.5^^82^781^7
 ;;^UTILITY(U,$J,358.3,11884,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11884,1,4,0)
 ;;=4^110.5
 ;;^UTILITY(U,$J,358.3,11884,1,5,0)
 ;;=5^Dermatophytosis of Body
 ;;^UTILITY(U,$J,358.3,11884,2)
 ;;=^33179
 ;;^UTILITY(U,$J,358.3,11885,0)
 ;;=110.4^^82^781^8
 ;;^UTILITY(U,$J,358.3,11885,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11885,1,4,0)
 ;;=4^110.4
 ;;^UTILITY(U,$J,358.3,11885,1,5,0)
 ;;=5^Dermatophytosis of Foot
 ;;^UTILITY(U,$J,358.3,11885,2)
 ;;=^33168
 ;;^UTILITY(U,$J,358.3,11886,0)
 ;;=288.03^^82^781^9
 ;;^UTILITY(U,$J,358.3,11886,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11886,1,4,0)
 ;;=4^288.03
 ;;^UTILITY(U,$J,358.3,11886,1,5,0)
 ;;=5^Drug Induced Neutropenia
 ;;^UTILITY(U,$J,358.3,11886,2)
 ;;=^334040
 ;;^UTILITY(U,$J,358.3,11887,0)
 ;;=054.10^^82^781^10
 ;;^UTILITY(U,$J,358.3,11887,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11887,1,4,0)
 ;;=4^054.10
 ;;^UTILITY(U,$J,358.3,11887,1,5,0)
 ;;=5^Genital Herpes
 ;;^UTILITY(U,$J,358.3,11887,2)
 ;;=^56853
 ;;^UTILITY(U,$J,358.3,11888,0)
 ;;=070.51^^82^781^11
 ;;^UTILITY(U,$J,358.3,11888,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11888,1,4,0)
 ;;=4^070.51
 ;;^UTILITY(U,$J,358.3,11888,1,5,0)
 ;;=5^Hepatitis C w/o Coma
 ;;^UTILITY(U,$J,358.3,11888,2)
 ;;=^331778
 ;;^UTILITY(U,$J,358.3,11889,0)
 ;;=053.9^^82^781^12
 ;;^UTILITY(U,$J,358.3,11889,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11889,1,4,0)
 ;;=4^053.9
 ;;^UTILITY(U,$J,358.3,11889,1,5,0)
 ;;=5^Herpes Zoster NOS
 ;;^UTILITY(U,$J,358.3,11889,2)
 ;;=^56946
 ;;^UTILITY(U,$J,358.3,11890,0)
 ;;=042.^^82^781^13
 ;;^UTILITY(U,$J,358.3,11890,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11890,1,4,0)
 ;;=4^042.
 ;;^UTILITY(U,$J,358.3,11890,1,5,0)
 ;;=5^HIV Disease
 ;;^UTILITY(U,$J,358.3,11890,2)
 ;;=^266500
 ;;^UTILITY(U,$J,358.3,11891,0)
 ;;=V15.81^^82^781^14
 ;;^UTILITY(U,$J,358.3,11891,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11891,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,11891,1,5,0)
 ;;=5^HX of Past Noncompliance
 ;;^UTILITY(U,$J,358.3,11891,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,11892,0)
 ;;=356.9^^82^781^15
 ;;^UTILITY(U,$J,358.3,11892,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11892,1,4,0)
 ;;=4^356.9
 ;;^UTILITY(U,$J,358.3,11892,1,5,0)
 ;;=5^Idiopathic Neuropathy
 ;;^UTILITY(U,$J,358.3,11892,2)
 ;;=^123931
 ;;^UTILITY(U,$J,358.3,11893,0)
 ;;=V68.1^^82^781^16
 ;;^UTILITY(U,$J,358.3,11893,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11893,1,4,0)
 ;;=4^V68.1
 ;;^UTILITY(U,$J,358.3,11893,1,5,0)
 ;;=5^Issue Repeat Prescription
 ;;^UTILITY(U,$J,358.3,11893,2)
 ;;=^295585
 ;;^UTILITY(U,$J,358.3,11894,0)
 ;;=176.0^^82^781^17
 ;;^UTILITY(U,$J,358.3,11894,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11894,1,4,0)
 ;;=4^176.0
 ;;^UTILITY(U,$J,358.3,11894,1,5,0)
 ;;=5^Kaposi's Sarcoma, Skin
 ;;^UTILITY(U,$J,358.3,11894,2)
 ;;=^267206
 ;;^UTILITY(U,$J,358.3,11895,0)
 ;;=528.6^^82^781^18
